Technetium-99

Endometrial Cancer

Institut de Cancérologie de LorraineUNKNOWNPhase 3Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

44 Active assets in the Endometrial Cancer cohort.

Asset / Sponsor	Phase	Rating
Tisotumab Vedotin Seagen Inc.	Phase 2	BBB
Lenvatinib Merck Sharp & Dohme LLC	Phase 3	BB
Pembrolizumab Eli Lilly and Company	Phase 3	BB
Carboplatin Eli Lilly and Company	Phase 3	BB
Cis-Diamminedichloroplatinum Ii Eli Lilly and Company	Phase 3	BB

View all 50 →

Same molecule, other indications

Technetium-99 is also rated in:

skin squamous cell carcinomaDormant

BB

Indicative · Phase 3

64 / 100

anus cancerDormant

BB

Indicative · Phase 3

64 / 100

cervical cancerDormant

B

Indicative · Phase 3

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.